Related Experiment Video
Updated: Jul 7, 2026
08:30
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
Published on: March 12, 2016
Brinzolamide
1University of Genoa, Laboratorio clinico anatomo-funzionale per diagnosi e il trattamento del glaucoma e della malattie neurooftalmologiche, Clinica Oculistica, Department of Neurological Sciences, Ophthalmology, Genetic, Italy. iester@unige.it
Expert Opinion on Pharmacotherapy
|March 4, 2008
Summary
Brinzolamide ophthalmic suspension 1% effectively lowers intraocular pressure (IOP) in primary open-angle glaucoma patients. This treatment demonstrated safety and tolerability, with no significant impact on corneal health or systemic parameters.
Area of Science:
- Ophthalmology
- Pharmacology
Background:
- Primary open-angle glaucoma (POAG) is a progressive optic neuropathy.
- Elevated intraocular pressure (IOP) is the main risk factor for POAG and optic nerve head (ONH) damage.
- IOP is the only treatable risk factor for POAG.
Purpose of the Study:
- To evaluate the efficacy and safety of brinzolamide ophthalmic suspension 1% in managing IOP.
- To assess the impact of brinzolamide on retinal blood flow.
- To determine the effects of brinzolamide on corneal parameters and systemic health.
Main Methods:
- Clinical trials involving patients with POAG.
- Administration of brinzolamide ophthalmic suspension 1% as monotherapy, adjunctive therapy, or post-cataract surgery.
- Monitoring of IOP, retinal blood flow, corneal thickness, corneal endothelium cell density, heart rate, blood pressure, and laboratory values.
Main Results:
- Brinzolamide ophthalmic suspension 1% reduced IOP by up to 18% from baseline.
- Retinal blood flow showed improvement with brinzolamide treatment.
- No significant changes in corneal thickness or endothelium cell density were observed after 18 months.
- Adverse events were mild and nonserious, with taste perversion being the most common non-ocular event.
- No clinically significant systemic effects on heart rate, blood pressure, or laboratory values were detected.
Conclusions:
- Brinzolamide ophthalmic suspension 1% is an effective topical carbonic anhydrase inhibitor for lowering IOP in POAG.
- The treatment is well-tolerated with a favorable safety profile regarding ocular and systemic parameters.
- Brinzolamide offers a safe and effective option for IOP management in POAG patients.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...